Saving changes...

Done

Error

Phase IV & Post-Marketing Surveillance

Phase IV & Post-Marketing Surveillance

Phase IV & Post-Marketing Surveillance

Danial Baker PharmD, FASHP, FASCP
Danial Baker PharmD, FASHP, FASCP
on behalf of Washington State University College of Pharmacy

$20.00 $ 20.00 $ 20.00

$20.00 $ 20.00 $ 20.00

$ 20.00 $ 20.00 $ 20.00
$ 20.00 $ 20.00 $ 20.00
Normal Price: $20.00 $20.00

Review:

Launch date: 15 Apr 2018

Expiry Date: 15 Apr 2021

Last updated: 03 Jul 2018

Reference: 187495

Exam is embedded in the course
No preview available
No Exam Available

Latest User Comments

I would like to...

Course Availability

This course is only available to trainees days after purchase. It would need to be repurchased by the trainee if not completed in the allotted time period. This course is no longer available. You will need to repurchase if you wish to take the course again.

Description

Overview of the Phase IV drug approval and post-marketing surveillance in the United States

Objectives

Phase IV Studies
• Describe the location of Phase IV studies with in the drug development process in the United States
• List the types of studies or activities that could be included in the Phase IV category
Drug Safety
• Identify which governmental agency is responsible for monitoring drug safety once a drug is approved by the FDA
• Describe the role of the pharmacists in reporting drug safety concerns after drug and biologic agents are approved and marketed in the United States
REMS
• Describe the role of Risk Evaluation and Mitigation Strategies
Danial Baker PharmD, FASHP, FASCP

Author Information Play Video Bio

Danial Baker PharmD, FASHP, FASCP
on behalf of Washington State University College of Pharmacy

Director, Continuing Education, College of Pharmacy, Washington State University

Current Accreditations

This course has been certified by or provided by the following Certified Organization/s:

  • Accreditation Council for Pharmacy Education (ACPE)
  • 1.50 Hours

Faculty and Disclosures

Additional Contributors

Conflicts Declared

Conflicts of Interest declaration by Author:

null

User Reviews (0)

Go Back

Loading...


Saving changes...

Done

Error